Skip to Main Content

Retevmo, a drug developed by Eli Lilly’s Loxo Oncology unit, shows efficacy in tumors beyond the lung and thyroid cancers where it is approved so long as those tumors bear a key genetic alteration, the company said.

Full data were released Sunday at a presentation at the virtual meeting of the American Association for Cancer Research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!